Cefuroxime for injection

This product is a first-generation cephalosporin, which has good antibacterial effect on some strains of Gram-positive cocci such as non-penicillinase-producing and penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococci, group A hemolytic streptococci, Streptococcus pneumoniae and viridans streptococci. Anaerobic Gram-positive bacteria are mostly sensitive to this product, while Bacteroides fragilis is resistant to it. Methicillin-resistant Staphylococci and Enterococci are resistant to this product. The effect of this product on Gram-positive and Gram-negative bacteria is similar to that of cephalexin. This product has a certain effect on gonococci and is also active against enzyme-producing gonococci; its activity against Haemophilus influenzae is poor.

The main ingredient of this product is cefradine, and its chemical name is (6R,7R)-7[(R)-2-amino-2-(1,4-cyclohexenyl)acetylamino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-146-carboxylic acid.

This product is white or off-white powder.

It is suitable for respiratory tract infections such as acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia, urinary and reproductive tract infections, and skin and soft tissue infections caused by sensitive bacteria.

Intravenous drip, intravenous injection or intramuscular injection, adults, 0.5-1.0g once, once every 6 hours, the maximum daily dose is 8g. Children (over 1 year old) 12.5-25mg/kg once according to body weight, once every 6 hours. When the creatinine clearance rate is greater than 20ml/min, 5-20ml/min or less than 5ml/min, the dose should be adjusted to 0.5g, 0.25g every 6 hours and 0.25g every 12 hours. When preparing intramuscular injection, add 2ml of injection water to the 0.5g bottle and deep intramuscular injection is required. When preparing intravenous injection, inject at least 10ml of injection water or 5% glucose injection into the 0.5g bottle respectively. The injection is completed within 5 minutes. When preparing intravenous drip, inject 10ml of appropriate diluent into the 0.5g bottle respectively, and then further dilute with sodium chloride injection or 5% glucose solution.

The adverse reactions of this product are mild and the incidence is low, about 6%. Gastrointestinal reactions such as nausea, vomiting, diarrhea, and upper abdominal discomfort are more common. The incidence of drug rash is about 1% to 3%. Pseudomembranous colitis, eosinophilia, positive reaction to direct Coombs test, peripheral blood leukocytopenia and neutrophil granulocyte reduction are seen in individual patients. A small number of patients may experience temporary increase in blood urea nitrogen, transient increase in serum aminotransferase and serum alkaline phosphatase. This product is painful when injected intramuscularly, and there are reports of phlebitis after intravenous injection.

This product is contraindicated in patients who are allergic to cephalosporins or have a history of anaphylactic shock or immediate reaction to penicillin.

1. This product and aminoglycoside antibiotics can inactivate each other. When the above drugs are given at the same time, they should be administered at different sites and the two types of drugs cannot be mixed in the same container. 2. This product cannot be mixed with other antibiotics. 3. Furosemide, ethacrynic acid, bumetanide and other strong diuretics, carmustine, streptozocin and other anti-tumor drugs, as well as glycopeptides and aminoglycoside antibiotics, etc., when used in combination with this product, may increase nephrotoxicity. 4. Probenecid can delay the renal excretion of this product. 5. This product contains sodium carbonate, so it is incompatible with calcium-containing solutions such as compound sodium chloride injection.

Seal tightly and store in a cool, dark place.

0.5g

Shantou Jinshi Sterilize Powder For Injection Co., Ltd.

• Founded in:

  1994-04-29

• Address:

  No. 36, Taishan Road, Shantou City

• Tax NO.:

  914405002798080307

• Registered Funds:

  17 million yuan

• Website:

  Log in to view

• Email:

  Log in to view